Thus, due to limited data on EZR in cervical cancer and stomach adenocarcinoma, the authors decided to further the clinical and biological characterization of the role of EZR in these cohorts, as well as to investigate the potential of a pharmacological ezrin inhibitor in cellular models of these tumor types. Here, EZR is linked to neoplasm.